Medivation Aims For 2010 Approval Of Alzheimer’s Drug Dimebon
This article was originally published in The Pink Sheet Daily
Executive Summary
The neuroprotectant's novel mechanism of action makes it a good candidate for Alzheimer's disease drug cocktails, CEO Hung says.
You may also be interested in...
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.
Industry Roundtable: Brains Behind Neurotech Discuss Innovation, Challenges Ahead
Neurotechnology Industry Organization Executive Director Zack Lynch and four neuroscience CEOs talk about issues facing the industry, including clinical trial design and funding development, during a roundtable discussion with “The Pink Sheet” DAILY.